outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
Published 1 year ago • 270 plays • Length 2:48Download video MP4
Download video MP3
Similar videos
-
3:33
an overview of the car t-cell therapy story
-
1:55
unmet needs in dlbcl: frontline therapy, car-t optimization, and clinical trial inclusion
-
1:49
a novel subcutaneous car-t therapy for the treatment of hematological malignancies
-
1:04
the major hurdles and emerging opportunities of car t-cell therapy
-
2:53
safety and efficacy of allogenic car-t cell treatment
-
1:16
the efficacy of car t-cell therapy in richter's transformation
-
1:27
car t-cells in all: an overview
-
5:09
the beginning of my allogeneic bone marrow transplant journey
-
3:14
car t-cell therapy explained (manufacturing process & how it works)
-
2:54
mediating the high expense of car t-cell therapy
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
2:06
car-t as a second-line therapy in the lymphoma treatment landscape
-
1:38
challenges of car-t therapy in the real-world setting
-
1:39
the role of myeloid cells in car-t cell therapy
-
4:10
car t-cell therapy for all
-
3:10
universal car-t therapy for t-all
-
1:37
the use of bispecifics and car t-cells in south america: challenges that remain
-
2:30
the future of car t-cell therapy
-
1:22
car t-cells in hemonc: where do we stand?
-
1:26
the safety and efficacy of allosct following car-t cell therapy for large b-cell lymphoma
-
4:02
the future of car-t and cellular therapy
-
2:56
the future landscape of car t-cell therapy